Table 1.

Patient disposition.

Disposition reason, n (%)	Ponatinib pretreated n = 29	Ponatinib naive n = 19	All patients N = 48
Patients treated
Treatment ongoinga	15 (51.7)	12 (63.2)	27 (56.3)
End of treatment	14 (48.3)	7 (36.8)	21 (43.8)
Primary reason for end of treatment
Physician decisionb	8 (27.6)	3 (15.8)	11 (22.9)
Adverse event	2 (6.9)	2 (10.5)	4 (8.3)
Patient/guardian decision	0	0	0
Progressive disease	2 (6.9)c	0	2 (4.2)c
Death	0	2 (10.5)	2 (4.2)
Technical problems	1 (3.4)d	0	1 (2.1)d
Protocol deviation	1 (3.4)e	0	1 (2.1)e

^aPatients ongoing at the time of the cutoff (January 6, 2021).

^bReasons for physician decision included loss of response (n = 3), loss or lack of response with transfer to stem cell transplant (n = 3), lack of efficacy (n = 2), to receive stem cell transplant (n = 2), and transfer to investigator-initiated trial (n = 1).

^cPatients with disease progression to accelerated phase.

^dPatient travel to trial site restricted due to COVID-19. Moved to a managed access program.

^ePatient required prohibited medication (hydroxyurea). Continued treatment under a managed access program.